Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by DSM-IV-TR criteria~* The current depressive episode must be equal to or greater than 8 weeks in duration~* Subjects must report a history for the current depressive episode of an inadequate response to no more than three adequate antidepressant treatments~Exclusion Criteria:~* Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug~* Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration~* Subjects with a current Axis I (DSM-IV-TR) diagnosis of: Delirium, dementia, amnestic or other cognitive disorder, Schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder~* Subjects with a clinically significant current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Phase B (Type: EXPERIMENTAL): Drug: OPC-34712 + ADT~Drug: Placebo + ADT
- Phase A (Type: PLACEBO_COMPARATOR): Drug: Placebo + ADT

Based on this trial design, predict the completion outcome and termination type (if applicable).